GlassScriptPhysician profile
Christopher Richard Morris
NPI 1295831733
$26,023.71
in general payments reported to CMS, 2019-2025
36 companies · $3,269 in 2025
The $3,269 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,315 · 2020: $2,968 · 2021: $3,724 · 2022: $3,620 · 2023: $4,367 · 2024: $3,760 · 2025: $3,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,124.97 |
| Education | $271.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,188.19 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $4,729.71 | 2019-2025 | |
| Janssen Biotech, INC. | $3,248.46 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,906.33 | 2019-2025 | |
| Pfizer INC. | $1,752.84 | 2019-2025 | |
| Ucb, INC. | $1,512.25 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,112.92 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $951.63 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $828.27 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $640.55 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $494.36 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $471.26 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $467.93 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $336.41 | 2019-2024 | Actemra |
| Regeneron Healthcare Solutions, INC. | $258.11 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.